6 assets in Hepatitis

Therapeutic assets addressing Hepatitis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Azathioprine Hepatitis	Therakos LLC	P2	CCC (53)
Infliximab Hepatitis	Therakos LLC	P2	CCC (53)
VITPSO Hepatitis	Therakos LLC	P2	CCC (53)
Vedolizumab Hepatitis	Therakos LLC	P2	CCC (50)
Hcv Dna Vaccine Ino-8000 Hepatitis	National Cancer Institute (NCI)	P1	CC (43)
Rocakinogene Sifuplasmid Hepatitis	National Cancer Institute (NCI)	P1	CC (43)